Association between triglyceride and high-density lipoprotein cholesterol change following fibrate therapy.
- Submitting institution
-
Brunel University London
- Unit of assessment
- 12 - Engineering
- Output identifier
- 031-97255-4464
- Type
- D - Journal article
- DOI
-
10.1016/j.dsx.2014.09.004
- Title of journal
- Diabetes Metab Syndr
- Article number
- -
- First page
- 212
- Volume
- 8
- Issue
- 4
- ISSN
- 1878-0334
- Open access status
- Out of scope for open access requirements
- Month of publication
- October
- Year of publication
- 2014
- URL
-
-
- Supplementary information
-
-
- Request cross-referral to
- -
- Output has been delayed by COVID-19
- No
- COVID-19 affected output statement
- -
- Forensic science
- No
- Criminology
- No
- Interdisciplinary
- Yes
- Number of additional authors
-
5
- Research group(s)
-
2 - Applied Mechanics & Structures
- Proposed double-weighted
- No
- Reserve for an output with double weighting
- No
- Additional information
- Fibric acid derivatives, known as fibrates, are a class of medications that lower blood triglyceride (TG) levels. High TG levels are found in diabetic patients who carry a significantly higher risk of atherosclerosis, and cardiovascular disease, especially coronary heart disease (CHD) and stroke. Fibrates are known to influence both, high-density lipoproteins cholesterol (HDL-C) and TG levels. Our study, based on 248 subjects, found a significant TG reduction regardless of the baseline patient characteristics including HDL-C levels.
- Author contribution statement
- -
- Non-English
- No
- English abstract
- -